[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583513":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":37,"responsibleParty":54,"collaborators":32,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":32,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":32,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":40,"whyStopped":32,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Sichuan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Radiation therapy combined with PD-1 inhibitor and chemotherapy group","EXPERIMENTAL","Low-Dose Radiation(2Gy\\*2-3d) +Stereotactic body radiation therapy (10Gy\\*3d) followed by Tislelizumab (200mg) with platinum-based doublet chemotherapy administered pre-operatively every 3 weeks for 3 cycles before surgical resection.",[13],"Drug: Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)",[9],[20,21],"Drug: Tislelizumab","Drug: Chemotherapy",[23],{"name":24,"affiliation":25,"role":26},"You Lu, MD. PhD","Study Principal Investigator","PRINCIPAL_INVESTIGATOR",[28,34],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Jianxin Xue, MD. Phd","CONTACT","18982251798",null,"killercell@163.com",{"name":24,"role":30,"phone":35,"phoneExt":32,"email":36},"+86 189 8060 1763","radyoulu@hotmail.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":42,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"West China Hospital of Sichuan University","RECRUITING","Chengdu","China","610041","CN",{"type":46,"coordinates":47},"Point",[48,49],104.06667,30.66667,{"lat":49,"lon":48},[52],{"name":53,"role":30,"phone":31,"phoneExt":32,"email":33},"Jianxin Xue, MD. PhD",{"type":26,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"You Lu","Chair of Division of Thoracic Tumor Multimodality Treatment","100583513","phase-2-low-dose-radiation--sbrt--tislelizumab-plus-platinum-based-chemotherapy-in-stage-a-b-non-small-cell-lung-cancer-100583513",false,"NCT06877299","Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer","Low-Dose Radiation + Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy As Neoadjuvant Therapy in Patients With Resectable StageⅡA-ⅢB Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 and ≤ 75 years;\n2. Patients with untreated stage IIA-IIIB non-small cell lung cancer, diagnosed cytologically or histologically (according to the AJCC 9th edition of thoracic tumor staging);\n3. Pulmonary lesions will be assessed as resectable or potentially resectable by a multidisciplinary team, including a thoracic surgeon;\n4. At least one imaging-measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1);\n5. Ability to provide tumor tissue or cell wax blocks that meet quality control standards for PD-L1 expression testing.\n\nExclusion Criteria:\n\n1. The pathology is small cell lung cancer (SCLC), including lung cancer mixed with SCLC and non-small cell lung cancer (NSCLC)；\n2. Patients with known EGFR-sensitive mutations or ALK fusion.\n3. Previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or another drug that stimulates or synergistically inhibits T cell receptors;\n4. Subjects with any known or suspected autoimmune disorder or immunodeficiency, with the following exceptions: hypothyroidism, hormone therapy is not needed, or well controlled at physiological dose; controlled type I diabetes;\n5. Active infection requiring systemic treatment.","ALL","18 Years","75 Years",{"count":68,"type":69},30,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","This phase II study aims to evaluate the efficacy and safety of low-dose radiation + SBRT + Tislelizumab plus platinum-based chemotherapy as neoadjuvant therapy for stage II-III non-small cell lung cancer.",[75,76],"Lung Cancer","Non-small Cell Lung Cancer",[78,79,80,81,82],"Neoadjuvant","Low Dose Radiotherapy","Stereotactic Body Radiotherapy","Immunotherapy","NSCLC","2025-12-29",{"date":85,"type":86},"2026-01-02","ACTUAL",{"date":88,"type":86},"2025-07-04",{"date":90,"type":69},"2028-01-01",{"name":5,"class":6},1]